regulatory
confidence high
sentiment negative
materiality 0.65
iCoreConnect Inc.: Nasdaq/NYSE listing notice — iCoreConnect receives Nasdaq deficiency notice after director resignation; cure period until May 2025
iCoreConnect Inc.
- Director Joseph Gitto resigned from board and audit committee on May 6, 2024, effective immediately.
- Nasdaq notified company on May 8, 2024 of non-compliance with Listing Rule 5605 (majority independent board, three independent audit committee members).
- Cure period runs until earlier of next annual shareholders' meeting or May 6, 2025 (or November 4, 2024 if meeting before November 4, 2024).
- Company plans to appoint one or more independent directors to the board and audit committee within the cure period.
- Notice has no immediate effect on listing or trading of ICCT common stock on Nasdaq Capital Market.